Advertisement

Acute drug test

  • A. Bayés de Luna
  • J. Guindo
  • S. García-Sánchez
  • P. Torner
  • R. Oter
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 110)

Abstract

Initially introduced by Lown et al.. [1–4], these authors demonstrated the efficacy of this test in the treatment of patients with malignant ventricular arrhythmias. The test consists of the administration of acute oral doses of antiarrhythmic drug so as to determine whether the drug can suppress the premature ventricular contractions. If this is the case, it is probable that chronic administration of the antiarrhythmic will be useful. The acute drug test also allows us to know if the drug has an arrhythmogenic effect. The aims of the acute drug test, therefore, are:
  1. a)

    to identify therapy for arrhythmias more scientifically and less empirically;

     
  2. b)

    to objectively prove whether the therapeutic efficacy of the drugs administered acutely is maintained with chronic administration;

     
  3. c)

    to avoid iatrogenic risks (specially arrhythmogenesis) of antiarrhythmic drugs.

     

Keywords

Ventricular Tachycardia Ventricular Arrhythmia Antiarrhythmic Drug Premature Ventricular Contraction Holter Monitoring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lown B, Graboys TB: Management of the patient with malignant ventricular arrhythmias. Am J Cardiol 1977; 39: 910.PubMedCrossRefGoogle Scholar
  2. 2.
    Graboys TB, Lown B, Podrid PJ, De Silva R: Longterm survival of patients with ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 1982; 50: 437.PubMedCrossRefGoogle Scholar
  3. 3.
    Graboys TB: Non-invasive assessment of antiarrhythmic drugs. In Bayés de Luna A, Betriu A, Permanyer G: Therapeutics in cardiology. Kluwer Academic Press, Dordrecht 1988, p. 59.Google Scholar
  4. 4.
    Graboys TB, Almeida EC, Lown B: Recurrence of malignant ventricular arrhythmias after antiarrhythmic drug withdrawal. Am J Cardiol 1986; 58: 59.PubMedCrossRefGoogle Scholar
  5. 5.
    Bayés de Luna A, Guindo J, Torner P, Borja J, Caturla MC, Garcia S, Dominguez JM, Oter R, Jané F: Value of effort testing and acute drug testing in the evaluation of antiarrhythmic treatment. Eur. Heart J 1987; 8 (Suppl A): 77.Google Scholar
  6. 6.
    Guindo J, Bayés de Luna A, Borja J et al.: Valoración terapéutica de la propafenona en pacientes con arritmias ventriculares potencialmente malignas mediante la prueba aguda incruenta farmacológica. Rev Lat Cardiol 1986; 7: 507.Google Scholar
  7. 7.
    Guindo J, Bayés de Luna A, Torner P et al.: Valor del test agudo incruento en el tratamiento de las arritmias ventriculares potencialmente malignas. Rev Esp cardiol 1987; 40 (Suppl I): 51Google Scholar
  8. 8.
    Josephson MR, Horowitz LN: Electrophysiologic approach to therapy of recurrent sustained ventricular tachycardia. Am J Cardiol 1979; 43: 631.PubMedCrossRefGoogle Scholar
  9. 9.
    Mason JW, Winkle RA: Accuracy of the ventricular tachycardia-induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med 1980; 303: 1073.PubMedCrossRefGoogle Scholar
  10. 10.
    Horowitz LN, Josephson ME, Kastor JA: Intracardiac electrophysiologic studies as a method for the optimization of drug therapy in chronic ventricular arrhythmia. Prog. Cardiovasc Dis 1980; 23: 81.PubMedCrossRefGoogle Scholar
  11. 11.
    Ruskin TN, Dimarco JP, Garan H: Out-of-hospital cardiac arrest. Electrophysiologic observations and selection of long-term antiarrhythmic therapy. N Engl J Med 1980; 303: 607.PubMedCrossRefGoogle Scholar
  12. 12.
    Swerdlow CD, Winkle RA, Mason JW: Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983; 308: 1436.PubMedCrossRefGoogle Scholar
  13. 13.
    Mitchell LB, Duff HJ, Manyari DE, Wyse DG: A randomized clinical trial of the noninasive and invasive approaches to drug therapy of ventricular tachycardia. N Engl J Med 1987; 317: 1681.PubMedCrossRefGoogle Scholar
  14. 14.
    Podrid PJ: Treatment of ventricular arrhythmia. Applications and limitations of noninvasive vs invasive approaches. Chest 1985; 88: 121.PubMedCrossRefGoogle Scholar
  15. 15.
    CAST Investigators. Preliminary Report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia supression after myocardial infarction. N Engl J Med 1989; 321: 406.CrossRefGoogle Scholar
  16. 16.
    Velebit V, Podrid P, Lown B: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982; 65: 886.PubMedCrossRefGoogle Scholar
  17. 17.
    Escoubet B, Coumel P, Poirier JM et al.: Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentations. Am J Cardiol 1985; 55: 696PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • A. Bayés de Luna
  • J. Guindo
  • S. García-Sánchez
  • P. Torner
  • R. Oter

There are no affiliations available

Personalised recommendations